TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02589314

Intervention type: DEVICE
Intervention: Mechanical periodontal therapy

Intervention type: PROCEDURE
Intervention: nonsurgical periodontal therapy
Study: NCT01300910

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Shang Ring
Description: The Shang Ring is a sterile device consisting of two concentric medical grade plastic rings: an inner ring with a silicone band and an outer, hinged ring. The inner ring fits inside the outer ring which will lock when snapped together. The Shang Ring comes in multiple sizes. The appropriate size is determined through use of a measuring strip. To ensure that men cannot remove the device prematurely, the locking mechanism must be broken open using a tool that is similar to a scalpel handle. Then, a pair of special scissors, specifically designed for this purpose, is used to remove the inner ring after healing

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Male circumcision
Description: A conventional surgical procedure will be performed, per WHO recommendations, involving: drawing a line to mark the amount of foreskin to be cut; cutting off the foreskin; hemostasis; and wound closure with sutures.
Study: NCT03311035

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Seton
Description: The identification of the primary tract of the fistula and the placement of the thread can be performed in one single step. a non-absorbable, braided thread is inserted . After excision of the external opening and the extrasphincteric parts of the fistula, the thread is grasped and is pulled out of the anus .The thread is cut in two parts. The mucosa is incised over the muscular bridge . One thread is tied snugly around the muscle; the other is tied loosely .The snugly tied seton has to be replaced after 14 days to provide appropriate tension to cut slowly trough the muscle. This can easily be achieved with the second loosely tied seton . A new thread is folded in the middle and connected to the opened sling of the loose seton using a special knot shown in.The old thread is removed and in the same maneuver two new setons are placed. Again, one thread is tied snugly around the remaining portion of the sphincter muscle; the other is tied loosely .

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LIFT technique
Description: The internal opening was identified . The intersphincteric plane was entered via a curvilinear incision corresponding to the site of the internal opening at the intersphincteric groove. The intersphincteric plane was developed by meticulous scissor and diathermy dissection up to the tract. Once identified, a small, right-angled clamp was hooked underneath or a tape passed round it. the tract was then transfixed close to the internal sphincter with 2/0 polyglactin suture . Saline was gently injected through the external opening to confirm that the tract was no longer patent and it was then divided distal to the point of ligation . After light traction, a segment of the distal tract was excised and, if needed, any defect in the external sphincter was closed. The intersphincteric incision wound was re-approximated loosely with interrupted 2/0 Vicryl. Partial core-out of the fistula tract was performed from the external opening to the external sphincter.
Study: NCT04175210

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy - 3 weeks
Description: Patients randomized to ARM 1 will receive whole breast radiotherapy of 4050cGY and a concomitant boost to the tumor bed of 4800cGY in 15 fractions

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy - 2 weeks
Description: Patients randomized to ARM 2 will receive whole breast radiotherapy of 3200cGY and a concomitant boost to the tumor bed of 4200cGY in 10 fractions.
Study: NCT04312529

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isokinetic test + EMG
Description: Isokinetic test:The isokinetic device is used to evaluate the strength of a subject. The test will be performed in two positions. This will determine the best position to activate shoulder muscles EMG (electromyography):it's a device that measures the electrical activity of muscles. This will allow us to record the maximum activity of the shoulder muscles during force tests.
Study: NCT03069950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Floxuridine (FUDR)
Description: 5-Fluouracil (5FU) (1000 mg/m2/day continuous infusion over two days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Floxuridine (FUDR)
Description: 5-Fluouracil (5FU) (1000 mg/m2/day continuous infusion over two days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan (CPT-11)
Description: Irinotecan (CPT) (150 mg/m2 IV over 30 min to an hour) on Day 1 and Day 15.
Study: NCT01328028

Intervention type: OTHER
Intervention: Testing of archived cervical cancer tissue samples
Description: Cervical samples will be tested for histopathology diagnosis and human papillomavirus deoxyribonucleic acid testing.

Intervention type: OTHER
Intervention: Data collection
Description: Log sheet
Study: NCT01790646

Intervention type: OTHER
Intervention: intubation
Description: intubation using Glidescope videolaryngoscope
Study: NCT00703846

Intervention type: DRUG
Group type: OTHER
Intervention: Ketoconazole
Description: Foam, 2%, Extina will be applied twice daily (morning and evening) to all seborrheic dermatitis lesions on the face, scalp, ears, neck, and chest. Study product should be applied at the first sign of a seborrheic dermatitis flare, and twice daily applications should continue until the area(s) has cleared. All symptom flares should be treated throughout the 12-month study period.
Study: NCT02474576

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous aponeurotomy
Description: The finger(s) with limited extension due to Dupuytrens disease and for which the patient desires treatment, will be treated by fine-needle percutaneous aponeurotomy under local anesthesia (outpatient procedure). This procedure is already routinely used in clinical practice ; our study aims at better describing the time-sustainability of its benefits.
Study: NCT02296710

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiographic and sleep apnea test
Description: Echocardiographic evaluation (Vivid 7, GE) of systolic and diastolic function of both ventricles as well as evaluation of apnea-hypopnea index and type of apnea (ApneaLink®)
Study: NCT03612063

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitbit Iconic HR and Garmin Vivosmart HR
Description: During testing, participants will wear two different wrist-worn heart rate monitors, the Polar H7 heart rate sensor, and will be connected to an ECG machine. Participants will be asked to perform a series of movements on a treadmill. Heart rate will be assessed under the following conditions:~1. At rest~2. 4 mph~3. 5 mph~4. 6 mph~5. 7 mph~6. 8 mph~7. 9 mph~8. Post-exercise 1 minute~9. Post exercise 2 minutes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitbit Iconic HR and TomTom Spark 3
Description: During testing, participants will wear two different wrist-worn heart rate monitors, the Polar H7 heart rate sensor, and will be connected to an ECG machine. Participants will be asked to perform a series of movements on a treadmill. Heart rate will be assessed under the following conditions:~1. At rest~2. 4 mph~3. 5 mph~4. 6 mph~5. 7 mph~6. 8 mph~7. 9 mph~8. Post-exercise 1 minute~9. Post exercise 2 minutes
Study: NCT02479217

Intervention type: DRUG
Intervention: Docetaxel

Intervention type: DRUG
Intervention: Xeloda

Intervention type: DRUG
Intervention: Xeloda

Intervention type: DRUG
Intervention: Xeloda
Study: NCT03449173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor
Study: NCT04215172

Intervention type: DRUG
Intervention: Macrolides
Description: administration of azithromycin three times weekly for six months
Study: NCT00764335

Intervention type: PROCEDURE
Intervention: total hip arthroplasty one side
Description: unilateral total hip arthroplasty

Intervention type: PROCEDURE
Intervention: total hip arthroplasty both sides
Description: bilateral total hip arthroplasty

Intervention type: PROCEDURE
Intervention: total hip arthroplasty both sides
Description: bilateral total hip arthroplasty
Study: NCT02796586

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Participants will be randomly assigned to group versus individual contraceptive counseling

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Counseling
Description: Participants will be randomly assigned to group versus individual contraceptive counseling
Study: NCT03279224

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Allogenic FMT
Description: Fifty (50) g of screened donor feces will be weighed and homogenized with 30 mL of sterile 0.9 N NaCl + 10% glycerol using a sterile 330 micron micro-filter-separated double-compartment polyethylene bag in the Stomacher® Paddle Blender.~2.The volume of fecal filtrate corresponding to fifty (50) g of donor stools will be transferred into a 50 mL Falcon tube with screw top and frozen at -80oC.~3. For colonoscopy administration, three (3) Falcon tubes of thawed FMT concentrated will be diluted to a total volume of 300 mL with 0.9N NaCl and will be transported to the endoscopy suite. In the endoscopy suite, the FMT product will be packaged into 6 x 50 ml syringes for patient delivery by colonoscopy.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Autologous FMT
Description: 1. Fifty (50) g of the participant's feces will be weighed and homogenized with 30 mL of sterile 0.9 N NaCl + 10% glycerol using a sterile 330 micron micro-filter-separated double-compartment polyethylene bag in the Stomacher® Paddle Blender.~3.The volume of fecal filtrate corresponding to fifty (50) g of participant's stools will be transferred into a 50 mL Falcon tube with screw top and frozen at -80oC.~3. For colonoscopy administration, three (3) Falcon tubes of thawed FMT concentrated will be diluted to a total volume of 300 mL with 0.9N NaCl and will be transported to the endoscopy suite. In the endoscopy suite, the FMT product will be packaged into 6 x 50 ml syringes for patient delivery by colonoscopy.
Study: NCT02283749

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Xofigo
Description: This is a radio-isotope
Study: NCT02500758

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Preparatory handwash
Description: Preparatory handwash follows the UNE-EN 12791 standard using a diluted soft soap, 200g/1000g, made in community pharmacy service and sterilize in autoclave. Washing hands were prepared without use of a brush for 1 minute with 10 ml of soft soap. After being rinsed with running tap water, they are thoroughly dried with paper towels.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Preparatory handwash
Description: Preparatory handwash follows the UNE-EN 12791 standard using a diluted soft soap, 200g/1000g, made in community pharmacy service and sterilize in autoclave. Washing hands were prepared without use of a brush for 1 minute with 10 ml of soft soap. After being rinsed with running tap water, they are thoroughly dried with paper towels.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Preoperative surgical scrubbing using 3% PCMX
Description: Both hands were scrubbed using a sterile disposable surgical scrub brush with plastic bristles on one side and a foam sponge on the other side. The bristled side was used to scrub the entire hands, including all nails, palm and back of the hand, and interdigital spaces, and the foam side was used to rub between the fingers. Each side of each finger, between fingers and back al palm of the hand were rubbed for two and a half minute. Then, the forearms were rubbed from the wrist to the elbow, maintaining the hand highest than the arm, using a minute to wash each side. Both hands were rinsed by current water in an one-way (from the fingertips to the elbow), and wiped with a sterile disposable towel, including nails and interdigital spaces.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative surgical scrubbing using 4% CHG
Description: Both hands were scrubbed using a sterile disposable surgical scrub brush with plastic bristles on one side and a foam sponge on the other side. The bristled side was used to scrub the entire hands, including all nails, palm and back of the hand, and interdigital spaces, and the foam side was used to rub between the fingers. Each side of each finger, between fingers and back al palm of the hand were rubbed for two and a half minute. Then, the forearms were rubbed from the wrist to the elbow, maintaining the hand highest than the arm, using a minute to wash each side. Both hands were rinsed by current water in an one-way (from the fingertips to the elbow), and wiped with a sterile disposable towel, including nails and interdigital spaces.
Study: NCT03083067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol
Description: On the foundation of basic treatment strategies, inhaled budesonide/formoterol（160ug/4.5ug）will be used as an intervention drug for patients in PIC group. When air quality index (AQI) is above 200, they will temporary add one inhalation of budesonide/formoterol（160ug/4.5ug）twice a day until the third day after AQI drops below 200.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tiotropium bromide
Description: Inhaled tiotropium bromide(18ug) will be used as routine medicine according to doctor's advice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium bromide
Description: Inhaled tiotropium bromide(18ug) will be used as routine medicine according to doctor's advice.
Study: NCT01929759

Intervention type: DRUG
Group type: OTHER
Intervention: Stribild (elvitegravir, cobicistat, emtricitabine and tenofovir)
Description: Switch from Atripla (efavirenz, emtricitabine and tenofovir) to Stribild (elvitegravir, cobicistat, emtricitabine and tenofovir)for total of 8 weeks
Study: NCT02189252

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epanova

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epanova

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epanova
Study: NCT03312361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15% oxygen
Description: Participants will inhale 15% oxygen for 2 hours to see how it affects them.
Study: NCT02524067

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multifactorial circadian concept
Description: Circadian light, systematic information, music, individual foreclosure
Study: NCT02641639

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosbretabulin tromethamine
Description: CA4P is a synthetic phosphorylated prodrug of CA4, a naturally occurring derivative of the South African willow tree, combretum caffrum. CA4P targets pre-existing tumor vasculature, resulting in an acute, reversible reduction in TBF that leads to central necrosis within tumors.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline for infusion
Study: NCT03934203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Film-coated tablet
Study: NCT02189252

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epanova

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lovaza

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lovaza

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lovaza

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lovaza
Study: NCT04978233

Intervention type: OTHER
Intervention: sociodemographic and health, daily self-assessment, and feasibility of using the Opal app for COVID
Description: The intervention consists of having confirmed COVID-19 infected participants register for the Opal app and complete a daily questionnaire on symptoms related to their physical and mental health as well as on certain key vital signs (e.g., oxygen saturation, heart rate, temperature). A nurse will check the questionnaire results each day and determine the need for a teleconsultation with an infectious disease physician. Participants will be followed up for a minimum of 14 days, depending on their symptoms.
Study: NCT02072018

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: H-100
Description: H-100 is a new compound to be applied to Peyronie's disease tissue with the intention of reducing disease symptoms.
Study: NCT03069950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan (CPT-11)
Description: Irinotecan (CPT) (150 mg/m2 IV over 30 min to an hour) on Day 1 and Day 15.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLUOROURACIL
Description: 5-Fluouracil (5FU) (1200 mg/m2/day continuous infusion over two days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLUOROURACIL
Description: 5-Fluouracil (5FU) (1200 mg/m2/day continuous infusion over two days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PANITUMUMAB
Description: Panitumumab (6 mg/kg IV over 60 min)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PANITUMUMAB
Description: Panitumumab (6 mg/kg IV over 60 min)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DEXAMETHASONE
Description: flat dose of 25 mg on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Leucovorin (LV) (400 mg/m2 IV over 30 min to an hour)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Leucovorin (LV) (400 mg/m2 IV over 30 min to an hour)
Study: NCT03220061

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: music therapy
Study: NCT02877459

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AeriSeal System
Description: Subjects will undergo two bronchoscopy procedures two months apart and will be treated with AeriSeal foam unilaterally, in two sub-segments during each bronchoscopy (4 segments treated in total).
Study: NCT03612063

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Garmin Vivosmart HR and TomTom Spark 3
Description: During testing, participants will wear two different wrist-worn heart rate monitors, the Polar H7 heart rate sensor, and will be connected to an ECG machine. Participants will be asked to perform a series of movements on a treadmill. Heart rate will be assessed under the following conditions:~1. At rest~2. 4 mph~3. 5 mph~4. 6 mph~5. 7 mph~6. 8 mph~7. 9 mph~8. Post-exercise 1 minute~9. Post exercise 2 minutes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitbit Iconic HR and Apple Watch III
Description: During testing, participants will wear two different wrist-worn heart rate monitors, the Polar H7 heart rate sensor, and will be connected to an ECG machine. Participants will be asked to perform a series of movements on a treadmill. Heart rate will be assessed under the following conditions:~1. At rest~2. 4 mph~3. 5 mph~4. 6 mph~5. 7 mph~6. 8 mph~7. 9 mph~8. Post-exercise 1 minute~9. Post exercise 2 minutes
Study: NCT04645264

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foley Catheter
Description: The patient is catheterized during surgery.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foley Catheter
Description: The patient is catheterized during surgery.
Study: NCT00684892

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chartis System
Description: Assessment of airway flow and pressure
Study: NCT01899443

Intervention type: OTHER
Intervention: Observation
Description: This is an observational study observing relationship between routine care and outcomes after total hip or knee arthroplasty.
Study: NCT00469911

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Spectroscopy
Description: Magnetic Resonance Spectroscopy is a noninvasive procedure that provides detailed body images on any plane.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ex vivo heart biopsy
Description: Heart transplant patients will have their normal clinical routine heart biopsy
Study: NCT01894035

Intervention type: DRUG
Intervention: Iloprost (Ventavis, BAYQ 6256)
Description: Patients Diagnosed with Pulmonary Arterial Hypertension, Functional Class NYHA/WHO III, for whom was prescribed inhaled Iloprost.
Study: NCT04722822

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: (Intervention) Recommending HPV vaccine for patients 9-10 years of age
Description: Providers within intervention practices will receive training which includes both standardized communication strategies and strategies for switching from 11-12 years to 9-10 years including: challenges with 11-12 strategy, long-term immunity, success of other practices and tips to help standardize to age 9-10. Trainings will be a combination of online and in-person or virtual. Annual trainings will be offered and providers will receive Maintenance of Certification credits (MOC) for participating. Providers will routinely recommend HPV starting at age 9 for all patients -- which is already approved for this vaccine but is not routinely recommended at age 9 years.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: (Control) Recommending HPV vaccine for patients 11-12 years of age
Description: Providers within control practices will receive a training on standardized communication for HPV vaccine including: using strong recommendations, using presumptive recommendation, providing specific phrases to use with parents, answering common questions and, HPV vaccine as a cancer prevention. Annual trainings will be offered and providers will receive professional development credit (MOC).